Editas Medicine (EDIT) Other Non-Current Liabilities (2015 - 2025)
Editas Medicine (EDIT) reported Other Non-Current Liabilities of $2.8 million for Q4 2025, down 8.37% year-over-year from $3.1 million in Q4 2024, and down 39.95% on a QoQ basis from $4.7 million in Q3 2025.
Editas Medicine (EDIT) has 9 years of Other Non-Current Liabilities data on file, last reported at $2.8 million in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 8.37% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (down 8.37% YoY) and the FY2025 annual result came in at $2.8 million, down 8.37% from the prior year.
- Other Non-Current Liabilities fell to $2.8 million in Q4 2025 per EDIT's latest filing, from $4.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $6.4 million in Q1 2025 and bottomed at $1.8 million in Q4 2023.
- The 3-year median for Other Non-Current Liabilities is $3.5 million (2024), against an average of $3.8 million.
- Peak annual rise in Other Non-Current Liabilities reached 83.21% in 2025, while the deepest fall reached 8.37% in 2025.
- Tracing EDIT's Other Non-Current Liabilities over 3 years: stood at $1.8 million in 2023, then jumped by 70.67% to $3.1 million in 2024, then decreased by 8.37% to $2.8 million in 2025.
- Per Business Quant, the three latest EDIT Other Non-Current Liabilities figures stand at $2.8 million (Q4 2025), $4.7 million (Q3 2025), and $4.6 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.82 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 4.59 Mn |
| Mar 31, 2025 | 6.36 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 3.47 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Dec 31, 2020 | 27.50 Mn |
| Mar 31, 2020 | 1,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Sep 30, 2019 | 1,000.00 |
| Jun 30, 2019 | 1,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | 293,000.00 |
| Sep 30, 2018 | 301,000.00 |
| Jun 30, 2018 | 305,000.00 |
| Mar 31, 2018 | 311,000.00 |
| Dec 31, 2017 | 317,000.00 |
| Sep 30, 2017 | 325,000.00 |
| Jun 30, 2017 | 328,000.00 |
| Mar 31, 2017 | 331,000.00 |
| Dec 31, 2016 | 396,000.00 |
| Sep 30, 2016 | 19,000.00 |
| Jun 30, 2016 | 21,000.00 |
| Mar 31, 2016 | 24,000.00 |
| Dec 31, 2015 | 289,000.00 |